A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 17, 2024

Primary Completion Date

May 30, 2027

Study Completion Date

May 30, 2027

Conditions

Lung Cancer

Interventions

DRUG

Tafolecimab

450mg Q4W ≤6cycle

DRUG

Sintilimab

200mg Q3W ≤2years

DRUG

Nab paclitaxel

130mg/m² Q3W 4-6cycles

DRUG

Docetaxel

75mg/m² Q3W 4-6cycles

DRUG

Gemcitabine

1250mg/m² Q3W 4-6cycles

Trial Locations (1)

RECRUITING

Beijing Chest Hospital, Capital Medical University, Beijing

All Listed Sponsors

lead

Jinghui Wang

OTHER